We have moved some posts about daratumumab and the drug development process to the Daratumumab trial thread.
Last edited:
My only comments are to encourage clarification on the comment, “Furthermore, the symptoms of ME/CFS overlap with those of viral infection. As a result, there is not the stereotyped history of post-infective illness seen, for instance, in Reiter’s syndrome, in which new symptoms appear several days after the acquisition of infection”, under the “Relation to Intracellular Infection” sub-heading. I am not sure that I agree with this position and would quote recent Long COVID examples where 12 weeks are needed to see the appearance of idiopathic, long-term fatigue, PEM, and associated symptoms (not including the immediate post-infection period where the impacts of acute inflammation may be observed via cardiac, lung, or other organ sequelae).
I am not sure exactly what the concern is about the evolution of symptoms. We were making the point that many features of ME/CFS, including fatigue, malaise, orthostatic intolerance, nausea and sensitivity to light and sound, are also features of acute viral infections such as EBV and Covid-19. This makes it more difficult to clearly separate the acute viral illness from the subsequent long term illness. The requirement of several weeks observation before a diagnosis of ME/CFS is made reflects this overlap. The PEM pattern of exacerbation after exertion may be hard to tease out early on when malaise and fatigue can vary, perhaps with periods of viraemia, and can also appear to follow exertion, although that is hard to pin down. Unlike Reiter's syndrome there is no very clear distinction between the initial viral and later ME/CFS symptoms themselves.
I think I understand what you’re saying here but there is a difference between a diagnosis and a definition of a disease for the purposes of a hypothesis.This is the fallacy of assuming that a diagnosis is a diachronic concept despite being made at time X.
I realise that this is very counterintuitive and inconvenient but those are the sorts of things I tend to turn my attention to!! If we talk of 'different illness' we have to be clear whether we are talking about cause or effect and whether it is now or how things turn out.
Diagnostic criteria are a mirage because they take none of this into account.
If you’re defining ME/CFS in accordance with CCC or NICE, then the statement that “Adult-onset illness mostly never fully resolves” appears to be misleading
I agree. I think precision around this issue is important in ME/CFS papers. It is useful if authors make a clear definition of the disease they believe they are talking about.Your hypothesis paper and your Concept of ME/CFS paper both reference the CCC and the 2021 NICE guideline. If you’re defining ME/CFS in accordance with CCC or NICE, then the statement that “Adult-onset illness mostly never fully resolves” appears to be misleading – at least to me and to others on here who probably know considerably more about the characteristics of ME/CFS and the epidemiological data that many of scientists who we hope will be reading your paper. If, on the other hand, for the purpose of your hypothesis you are defining ME/CFS as an illness that mostly never fully resolves in cases of adult onset (which would be a valid definition), then I think you need to make that clear.
You said before that you may re-word the paragraph in question, and I agree that that would be worthwhile, if you’ve not already done so.
I don't think we have solid evidence that most people who fit the CCC at six months have an illness that never fully resolves. From my reading of papers and accounts and the experience of my own family, I don't actually believe that that is true.Most people who study the illness appear to agree that most people who fit CCC have an illness that never fully resolves. It isn't part of CCC but then it shouldn't be, because CCC is designed to identify people whose illness has a particular pattern now.
But CCC only requires symptoms for 6 months for adults, and as far as I’m aware it makes no reference to monophasic improvement, which I suspect may be highly relevant in predicting long-term outcomes – although I’m not aware of any data on that.I think the idea that ME/CFS is a disease that does not fade away in a [monophasic] fashion over a period of months after an infection is widely accepted. A number of research studies require subjects to have had the illness for at least two years in recognition of the fact that monophonic resolving PVF can take nearly that long.
I’ve had different experiences.I don't think we have solid evidence that most people who fit the CCC at six months have an illness that never fully resolves. From my reading of papers and accounts and the experience of my own family, I don't actually believe that that is true.
In fact, given the large numbers of people who probably meet modern definitions of ME/CFS and who do recover in the first 12 months, I actually think it is quite likely that most people who fit such definitions at any one time do recover.
It can take a long time to recognise the patterns relating exertion to later symptoms, though; our reality is so different to the common understanding of how exertion impacts bodies. For the first ten years of being sick, I thought it was a problem that just mysteriously disappeared and reappeared nonsensically. So I wouldn't put total faith in the way that newly sick people are interpreting their patterns of illness and which events they're connecting symptoms to.Most of the people that recovered did not retrospectively describe delayed reactions to exertion, only prolonged and disproportionate. It was «I feel terrible after doing this», not «something hit me like a train the day after doing this».
I don't think we have solid evidence that most people who fit the CCC at six months have an illness that never fully resolves.
But CCC only requires symptoms for 6 months for adults, and as far as I’m aware it makes no reference to monophasic improvement,
What is the source of the 80%? The data is of course a mess, with poor characterisation of ME/CFS, especially in those early months.You may be right but we have traditionally had a figure of around 80% not resolving. That may be too high but it is what is quoted. Do we have any better data?
We mentioned before the problem with saying that hardly anyone recovers from ME/CFS is that creates a situation where anyone who reasonably believes that they had ME/CFS and recovers feels special, and may promote whatever they were trying at the time as the cure. If lots of people are recovering in that first year or two, and they do seem to, then that is a lot of people feeling as though they have something important to share about brain retraining or LP or gratitude journalling.I am quite surprised that patients are concerned about saying that adult disease mostly does not resolve because they are usually keen to point out that it is
n't just a phase that will go away.
I think it’s more accurate to say that it is not unusual for patients be be diagnosed with ME/CFS and recover within 2 years but that recovery is unusual thereafter – as I think has been said earlier in this thread.I am quite surprised that patients are concerned about saying that adult disease mostly does not resolve because they are usually keen to point out that it is
n't just a phase that will go away.
The analysis in this article suggests that the wage income for persons diagnosed with G93.3 starts to deviate from their control groups' wages years before the diagnosis. The sharpest decline starts around 3 years before and lasts until a year after diagnosis, then stabilizes at a very low level. The consumption of sick-leave benefits starts increasing even before that, and also taxable transfers begin to deviate from the control groups’ as early as 5–6 years before diagnosis, gradually replacing wage income and sick-leave benefits.
Only a small share of the G93.3 cases who made no or very low wages around the time of the diagnosis experienced a positive wage development in the following years. In the 2016 cohort, 57% of the 1524 cases showed no improvement, 38% deteriorated, and only 5% improved somehow over the 3 years studied. Improvements were small. Only three of the 733 persons who made less than NOK(2018) 100,000 earned wages corresponding to a median wage 3 years later. Although less certain, the longer-term timelines based on the full sample of cases from 2009 to 2018 suggest similar trajectories.
Could you explain this point in layman’s terms?This is basically the diachronic/synchronic point.
Could you explain this point in layman’s terms?
The development of the theory is entirely orthogonal to what we have otherwise seen in ME/CFS research.
I agree that the sex ratio may be misleading and on its own would be a weak point to build a theory on. If anything one would build an autoantibody theory. But the combination of all the considerations drove me away from that simple solution.With the current diagnostic uncertainty, it’s hard to understand what exactly the sex ratio might tells us, especially if for example the condition may be made up of different conditions both with a very different sex ratio (say a T-cell mechanism slightly male dominated and a B-cell mechanism with a 9:1 ratio).
for example the condition may be made up of different conditions both with a very different sex ratio (say a T-cell mechanism slightly male dominated and a B-cell mechanism with a 9:1 ratio).
I think because unwinding requires some further readjustment of the adaptive immune cell repertoire - if you like the plasticity of the T cell repertoire (because B cell dynamics do not change much with age). Early on it may be easier for rogue T cell populations to arise or expand but equally easier for balancing out populations to come along and say 'hey, you shouldn't really be doing that'. As time goes by the T cell repertoire is believed to become more static, with thymic involution. It doesn't become immutable, and thymic activity does not cease, but it makes sense that the T cell recognition system is learning how to produce a balanced defence system mostly in early life. Unlike B cells, T cell populations include both responders and suppressors/regulators and either may expand.If the B-cell repertoire broadens with age and there is an accumulation of low-affinity IgG antibodies which increases the likelihood of FcγRI activation, but ME/CFS onset doesn’t increase with age because there are other mechanisms that counterbalance this (macrophages or T-cells being less “eager” less IFNg) if the second things are part of the positive feedback loops how do you not get higher chances of resolution of symptoms in older people?
Would someone be able to help me by explaining what «orthogonality» means in this context?
As someone who had the same question and had to Google: independent or not influenced by existing ideas or assumptions
Thank you!Literally, it means in a direction that has nothing in common with what has been indicated before - at right angles. It generates a cotangent of ZERO.
So it’s orthagonal in relation to previous ideas, not the data. That’s what was throwing me off.